Month: September 2022

Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support potential to use significantly higher doses of balixafortide than those previously investigated Additional observations indicate potential for stimulating prolonged stem cell mobilization, a potentially key advantage in implementing hematopoietic stem cell transplantationALLSCHWIL, Switzerland, Sept. 22, 2022 (GLOBE NEWSWIRE) — Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the results of a Phase 1 clinical trial with balixafortide (“BLX”), a potent, specific and highly selective macrocycle inhibitor of CXCR4. This study was undertaken to investigate whether dosing of BLX needs to be adjusted in patients with renal...

Transformation to pure-play Innovative Medicines company nears completionFocusing strategy on five core Therapeutic Areas, key technology platforms, and the USAdvancing eight in-market brands with multi-billion dollar peak sales potential and prioritizing pipeline to focus on high-value NMEsContinuing to deliver growing sales, Core Op Inc, and cash flows with consistent shareholder friendly capital allocationBasel, September 22, 2022 — Novartis executives are meeting investors and industry analysts in Basel today, sharing insights into the updated company strategy at the annual Meet Novartis Management event. The meeting will allow participants to learn more about Novartis journey to unite technology leadership in Research and Development with novel access approaches, helping to alleviate some of society’s greatest disease...

         Global Bioenergies: Successful completion of REWOFUEL project Paris, 22 September 2022 – Global Bioenergies announces the end of the REWOFUEL project, which ran from 1 June 2018 to 30 June 2022. This project brought together several European industries such as Repsol, Sekab and Fibenol, with the objective of demonstrating the conversion of wood residues into sustainable high-performance components for road and aviation fuels, and thus participate to the decarbonization efforts of ground and air transportation. The project was coordinated by Global Bioenergies and received €13.8 million in funding from the European Horizon 2020 research and innovation programme. The project, otherwise known by its full name, “Residual Wood Conversion to High-performance drop-in Biofuels”, was funded under contract n° 792104 through the Innovation...

DELTA, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) — WestBond Enterprises Corporation (TSX-V: WBE) is pleased to report that all matters were approved at the Company’s Annual General shareholders meeting (the “Meeting”) held on August 31, 2022. At the Meeting the Company’s shareholders re-elected all of the Company’s current board of directors, Gennaro Magistrale, J. Douglas Seppala, D. Dan Dawson and Peter R. Toigo as well as approved the re-appointment of the Company’s current auditor, PricewaterhouseCoopers LLP. The Company’s shareholders also approved the adoption of a new 10% rolling stock option plan in accordance with the requirements of the TSX Venture Exchange. For further information please contact: Gennaro Magistrale Chief Executive Officer, President and DirectorWestBond Enterprises Corporation101 – 7403 Progress...

CALGARY, Alberta, Sept. 21, 2022 (GLOBE NEWSWIRE) — Maxim Power Corp. (“MAXIM” or the “Corporation”) (TSX: MXG) provides updates on its 204 MW Milner 2 (“M2”) operations and the Combined Cycle Gas Turbine (“CCGT”) expansion of M2 project. M2 OPERATIONS AND CCGT PROJECT UPDATES As previously reported, M2 commenced cold commissioning activities related to the CCGT expansion project in the third quarter of 2022. These activities include taking the M2 gas turbine offline to allow for the connection of the heat recovery steam generator, steam turbine and related components. As a result of these activities, the M2 facility has been offline since early September. MAXIM anticipates that the CCGT expansion of M2 will begin hot commissioning activities early in the fourth quarter of 2022, which will result in intermittent...

OAKLAND, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — Today, Vice President Kamala Harris and US Treasury Secretary Janet L. Yellen announced that the US Treasury Department completed $671 million in preferred stock investments in ten Community Development Financial Institutions (“CDFI”) or Minority Depository Institutions (“MDI”) headquartered in California under the Emergency Capital Investment Program (“ECIP”). Bay Community Bancorp, (OTC Pink: CBOBA) (the “Company”), previously announced that its wholly-owned subsidiary, Community Bank of the Bay, (the “Bank”) a San Francisco Bay Area commercial bank and California’s first FDIC insured CDFI with full-service offices in Oakland, Danville and San Mateo, completed a $119.4 million investment from the US Treasury Department on June 7, 2022. The Company’s $119.4 million investment...

MONACO, Sept. 21, 2022 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has purchased its common shares in the open market and exercised a purchase option for an LR2 product tanker that is currently leased. Purchase of Common Shares The Company purchased 137,459 of its common shares in the open market at an average price of $43.27 per share as part of the Company’s securities repurchase program. The Company has $169.1 million remaining under its securities repurchase program as of the date of this press release. The acquired common shares are being held as treasury shares. The Company expects to repurchase any securities in the open market, at times and prices that are considered to be appropriate by the Company, but is not obligated under the terms of the program...

Montrouge, France, September 21, 2022 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) in the form of a partial clinical hold on its VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) Phase 3 clinical study. In the partial clinical hold letter, the FDA specifies changes to elements of the VITESSE protocol with the intent for the trial to support a future BLA submission. Within the FDA’s communication, the modifications address design elements, including the statistical analysis of adhesion, minimum daily wear time and technical alignments in methods of categorizing data,...